A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

NCT02202759 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision, No Safety or Efficacy Concerns

Conditions

Adenocarcinoma of the Stomach
Gastroesophageal Junction Expressing Guanylyl Cyclase C

Interventions

DRUG: MLN0264

Sponsor

Millennium Pharmaceuticals, Inc.